Radiobismuth for Therapy

Martin W. Brechbiel, Ekaterina Dadachova

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)
Original languageEnglish (US)
Title of host publicationBiological Chemistry of Arsenic, Antimony and Bismuth
PublisherJohn Wiley and Sons
Pages311-329
Number of pages19
ISBN (Print)9780470713907
DOIs
StatePublished - Nov 15 2010

Fingerprint

Therapeutics

Keywords

  • 213Bi and 212Bi, metallic in nature - chelation chemistry or bifunctional chelators for antibody linkage
  • Cancer treatment, and surgery - external beam radiation therapy and chemotherapy
  • Chemo-resistance and radio resistance - acquired by tumors, in conventional therapies
  • Landmark clinical trial, Memorial Sloan-Kettering Cancer Center - 213Bi-labeled humanized anti-CD33 monoclonal antibody
  • Monoclonal antibodies (mAbs) - viable strategy for therapeutic delivery
  • Radiobismuth for therapy
  • Radioimmunotherapy of experimental fungal, bacterial and viral infections - and 213bi-labeled antibodies
  • Targeted a-therapy versus targeted b-therapy
  • Targeted radiation therapy - stable sequestration of radionuclide in vivo, delivery of radiation to tumors
  • Targeting vectors, Murine mAbs - against tumor associated antigens (TAA), and multitudes of preclinical studies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Brechbiel, M. W., & Dadachova, E. (2010). Radiobismuth for Therapy. In Biological Chemistry of Arsenic, Antimony and Bismuth (pp. 311-329). John Wiley and Sons. https://doi.org/10.1002/9780470975503.ch13

Radiobismuth for Therapy. / Brechbiel, Martin W.; Dadachova, Ekaterina.

Biological Chemistry of Arsenic, Antimony and Bismuth. John Wiley and Sons, 2010. p. 311-329.

Research output: Chapter in Book/Report/Conference proceedingChapter

Brechbiel, MW & Dadachova, E 2010, Radiobismuth for Therapy. in Biological Chemistry of Arsenic, Antimony and Bismuth. John Wiley and Sons, pp. 311-329. https://doi.org/10.1002/9780470975503.ch13
Brechbiel MW, Dadachova E. Radiobismuth for Therapy. In Biological Chemistry of Arsenic, Antimony and Bismuth. John Wiley and Sons. 2010. p. 311-329 https://doi.org/10.1002/9780470975503.ch13
Brechbiel, Martin W. ; Dadachova, Ekaterina. / Radiobismuth for Therapy. Biological Chemistry of Arsenic, Antimony and Bismuth. John Wiley and Sons, 2010. pp. 311-329
@inbook{a5faa0a03575464e8d75ea12128e822b,
title = "Radiobismuth for Therapy",
keywords = "213Bi and 212Bi, metallic in nature - chelation chemistry or bifunctional chelators for antibody linkage, Cancer treatment, and surgery - external beam radiation therapy and chemotherapy, Chemo-resistance and radio resistance - acquired by tumors, in conventional therapies, Landmark clinical trial, Memorial Sloan-Kettering Cancer Center - 213Bi-labeled humanized anti-CD33 monoclonal antibody, Monoclonal antibodies (mAbs) - viable strategy for therapeutic delivery, Radiobismuth for therapy, Radioimmunotherapy of experimental fungal, bacterial and viral infections - and 213bi-labeled antibodies, Targeted a-therapy versus targeted b-therapy, Targeted radiation therapy - stable sequestration of radionuclide in vivo, delivery of radiation to tumors, Targeting vectors, Murine mAbs - against tumor associated antigens (TAA), and multitudes of preclinical studies",
author = "Brechbiel, {Martin W.} and Ekaterina Dadachova",
year = "2010",
month = "11",
day = "15",
doi = "10.1002/9780470975503.ch13",
language = "English (US)",
isbn = "9780470713907",
pages = "311--329",
booktitle = "Biological Chemistry of Arsenic, Antimony and Bismuth",
publisher = "John Wiley and Sons",

}

TY - CHAP

T1 - Radiobismuth for Therapy

AU - Brechbiel, Martin W.

AU - Dadachova, Ekaterina

PY - 2010/11/15

Y1 - 2010/11/15

KW - 213Bi and 212Bi, metallic in nature - chelation chemistry or bifunctional chelators for antibody linkage

KW - Cancer treatment, and surgery - external beam radiation therapy and chemotherapy

KW - Chemo-resistance and radio resistance - acquired by tumors, in conventional therapies

KW - Landmark clinical trial, Memorial Sloan-Kettering Cancer Center - 213Bi-labeled humanized anti-CD33 monoclonal antibody

KW - Monoclonal antibodies (mAbs) - viable strategy for therapeutic delivery

KW - Radiobismuth for therapy

KW - Radioimmunotherapy of experimental fungal, bacterial and viral infections - and 213bi-labeled antibodies

KW - Targeted a-therapy versus targeted b-therapy

KW - Targeted radiation therapy - stable sequestration of radionuclide in vivo, delivery of radiation to tumors

KW - Targeting vectors, Murine mAbs - against tumor associated antigens (TAA), and multitudes of preclinical studies

UR - http://www.scopus.com/inward/record.url?scp=79960539306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960539306&partnerID=8YFLogxK

U2 - 10.1002/9780470975503.ch13

DO - 10.1002/9780470975503.ch13

M3 - Chapter

SN - 9780470713907

SP - 311

EP - 329

BT - Biological Chemistry of Arsenic, Antimony and Bismuth

PB - John Wiley and Sons

ER -